Evaluation of molecular strategies to develop a live dengue vaccine

Clinical and Diagnostic Virology

Volumn 10, Issue 2-3, 1998, Pages 173-179

  Lai, C J ^a   Bray, M ^a   Men, R ^a   Cahour, A ^a   Chen, W ^a   Kawano, H ^a   Tadano, M ^a   Hiramatsu, K ^a   Tokimatsu, I ^a   Pletnev, A ^a   Arakai, S ^a   Shameem, G ^a   Rinaudo, M ^a  

^a Laboratory of Clinical Infectious Diseases   (United States)

Author keywords

Chimeric viruses; Deletion mutants; Dengue haemorrhagic fever dengue shock syndrome (DHF DSS); Dengue virus; Live vaccine

Indexed keywords

CAPSID PROTEIN; DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS PROTEIN;

CONFERENCE PAPER; DELETION MUTANT; DENGUE; DENGUE VIRUS; GENE TARGETING; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SHOCK; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; GENE DELETION; HUMANS; IMMUNIZATION; MACACA MULATTA; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; VACCINES, ATTENUATED; VACCINES, DNA; VIRAL VACCINES; VIRUS REPLICATION;

ANIMALIA; DENGUE VIRUS; MACACA MULATTA; MIRIDAE; RNA VIRUSES; SIMIAE;

EID: 0032527427     PISSN: 09280197     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0197(98)00035-X     Document Type: Conference Paper

References (25)

1. Bhamarapravati N., Yoksan S., Chayaniyayothin T., Angsubphakorn S., Bunyaratvej A. Immunisation with a live attenuated dengue 2 virus candidate vaccine (16681-PDK53): Clinical, immunological and biological responses in adult volunteers. Bull WHO. 65:1987;189-195.
2. Bray M., Lai C.J. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci USA. 88:1991;10342-10346.
3. Brinton M.A., Fernandez A.V., Disposito J.H. The 3′-nucleotides of flavivirus genomic RNA form a conserved secondary structure. Virology. 153:1986;113-121.
4. Brinton M.A, Disposito J.H. Sequence and secondary structure analysis of the 5′-terminal region of the flavivirus genome RNA. Virology. 162:1988;290-299.
5. Cahour A., Pletnev A., Vazeille-Falcoz M., Rosen L., Lai C.J. Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology. 207:1995;68-76.
6. Chambers T.J., Hahn C.S., Galler R., Rice C.M. Flavivirus genome organisation, expression, and replication. Annu Rev Microbiol. 44:1990;649-688.
7. Chen W., Kawano H., Men R., Clark D., Lai C.J. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol. 69:1995;5186-5190.
8. Edelman R., Tacket C.O., Wasserman S.S., Vaughn D.W., Eckels K.H., Dubois D.R., Summers P.L., Hoke C.H. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cells culture is attenuated and immunogenic for humans. J Infect Dis. 170:1994;1448-1455.
9. Hahn C.S., Hahn Y.S., Rice C.M., Lee E., Dalgarno L., Strauss E.G., Strauss J.H. Conserved elements in the 3′ untranslated region of flavivirus RNAs and potential cyclisation sequences. J Mol Biol. 198:1987;33-41.
10. Hoke C.H., Malinoski F.J., Eckels K.H., Scott R.M., Dubois D.R., Summers P.L., Simms T., Burrous J., Hasty S.E., Bancroft W.H. Preparation of an attenuated dengue 4 (341750 CARIB) virus vaccine. Safety and immunogenicity in humans. Am J Trop Med Hyg. 43:1990;219-226.
11. Hotta S. Experimental studies on dengue. Isolation, identification and modification of the virus. J Infect Dis. 90:1952;1-9.
12. Kuhn R.J., Griffin D.E., Zhang H., Niesters H.G.M., Strauss J.H. Attenuation of sindbis virus neurovirulence by using defined mutations in non-translated regions of the genome RNA. J Virol. 66:1992;7121-7127.
13. Lai C.J., Zhao B., Hori H, Bray M. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci USA. 88:1991;5139-5143.
14. Lai C.J., Men R., Pethel M., Bray M. Infectious RNA transcribed from stably cloned dengue virus cDNA: Construction of growth-restricted dengue virus mutants. Chanock R.M., Ginsberg H., Brown F., Lerner R.A. Vaccines 92: Modern Approaches to New Vaccines Including Prevention of AIDS. 1992;265-270 Cold Spring Harbor Laboratory Press, New York.
15. Mackow E., Makino Y., Zhao B., Zhang Y.M., Markoff L., Buckler-White A., Guiller M., Chanock R., Lai C.J. The nucleotide sequence of dengue type 4 virus: Analysis of genes coding for non-structural proteins. Virology. 159:1987;217-228.
16. Men R., Bray M., Clark D., Chanock R.M., Lai C.J. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol. 70:1996;3930-3937.
17. Monath T. Dengue: The risk to developed and developing countries. Proc Natl Acad Sci. 91:1994;2395-4000.
18. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH Nucleotide sequence of yellow fever virus: Implications for flavivirus gene expression and evolution. Science. 229:1985;726-733.
19. Rosen L. Experimental infection of new world monkeys with dengue and yellow fever viruses. Am J Trop Med Hyg. 7:1958;406-410.
20. Rosen L. Dengue in Greece in 1972 and 1928 and the pathogenesis of dengue hemorrhagic fever: New data and different conclusion. Am J Trop Med Hyg 1986;35:642-53.
21. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science 1945; 101:640-2.
22. Sabin AB, Research on dengue during World War II. Am J Trop Med Hyg 1955;1:30-50.
23. Schlesinger RW, Gordon E, Frankel JW, Winter JW, Patterson PR, Dorrance WR. Clinical and serological reponse of man to immunisation with attenuated dengue and yellow fever viruses. J Immunol 1956;77:352-64.
24. Schlesinger RW. Edngue Viruses. Virology Monographs, vol. 16, 1977:1-132.
25. Zhao B., Mackow E., Buckler-White A., Markoff L., Chanock R.M., Lai C.J. Cloning full length dengue 4 viral DNA sequences: Analysis of genes coding for structural proteins. Virology. 155:1986;77-88.